Doxorubicin Inhibits Tat-Dependent Transactivation of HIV Type 1 LTR
Authors:
- Masahiko KurabayashiMKMasahiko Kurabayashi
- Larry KedesLKLarry Kedes
- 1 May 1996
- journal article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 12 (7) , 569-576
Abstract
Tat, the human immunodeficiency virus (HIV)-encoded transcription factor, is vital for HIV replication and transcription. Any drug that inhibits Tat's activity is a valuable candidate for chemotherapeutic applications. We show here that doxorubicin (Dox), a well-known anticancer drug and its derivative, daunomycin, inhibit the ability of Tat to activate the HIV-1 LTR. We contransfected HeLa cells with pSV40TAT and a chloramphenicol acetyltransferase gene driven by an HIV LTR promoter. CAT transcription was vigorously stimulated many fold by Tat production but the effect of Tat was inhibited by Dox in a dose-dependent manner. The transcriptional activation domain of Tat, located in its 67 amino terminal residues, remains Dox sensitive. A TAR-deleted reporter gene with a Gal binding domain is transactivated by a Gal-Tat fusion protein. This transcription complex retains a high level of activity in the presence of Dox, suggesting that Dox primarily affects RNA-Tat, rather than DNA-Tat, mediated transactivation. RNA gel mobility analysis reveals that Dox does not affect the binding of Tat to TAR-RNA in vitro but does increase the binding activity of cellular nuclear proteins with TAR-RNA. Induction or activation of such TAR-binding proteins in cells that might interfere with the activity of Tat could explain the observed inhibitory effects of Dox on Tat-activated transcription. These results suggest that Dox may have chemotherapeutic effects on HIV expression mediated through TAR RNA.Keywords
This publication has 44 references indexed in Scilit:
- Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophagesAntiviral Research, 1992
- HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors.Genes & Development, 1992
- The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function.Genes & Development, 1991
- tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.Genes & Development, 1991
- Refolded HIV-1 tat protein protects both bulge and loop nucleotides in TAR RNA from ribonucleolytic cleavageBiochemistry, 1991
- Control of human immunodeficiency virus replication by the tat, rev, nef and protease genesCurrent Opinion in Immunology, 1991
- Trans-activation by HIV-1 Tat via a heterologous RNA binding proteinCell, 1990
- The trans-activator gene of the human T cell lymphotropic virus type III is required for replicationCell, 1986
- Trans -Activator Gene of Human T-Lymphotropic Virus Type III (HTLV-III)Science, 1985
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976